Moving Pipeline Diligence Beyond Mechanism-of-Action Slide Decks
During biotech crossover financings, licensing negotiations, and Phase III pivotal site selection, diligence teams devote exhaustive attention to preclinical pharmacology and Phase Ib waterfall plots while treating clinical execution timelines as fixed calendar assumptions. Yet our empirical audit of 54,890 Phase II and Phase III protocols proves that operational execution drives value destruction just as decisively as clinical biology: 1,629 trials collapsed purely from slow recruitment, and closed Oncology studies terminate nearly half the time (47.35%).
To replace qualitative CRO assurances with hard empirical baselines, Protocol Ledger links 784,367 deduplicated protocol-to-hospital execution arcs across 22,436 canonical medical centers and 4,879 sponsors. Below is a five-gate quantitative auditing framework built directly from reconciled federal records.
Gate 1 & Gate 2: Hospital Competing-Trial Congestion and Campus Entity Resolution
Emerging oncology and immunology biotechs frequently tout site lists anchored exclusively by marquee NCI-designated Comprehensive Cancer Centers. While academic hubs provide indispensable translational prestige, Table 1 reveals extraordinary concurrent competing-protocol loads at top U.S. academic campuses: MD Anderson Cancer Center runs 1,087 active Phase II/III protocols simultaneously (576 actively recruiting today), Washington University / Siteman Cancer Center runs 902, Memorial Sloan Kettering runs 832, Mayo Clinic Rochester runs 780, and California's flagship UCLA Jonsson (701), Stanford (644), and UCSF Helen Diller (641) campuses each manage over six hundred concurrent studies.
Without canonical entity resolution, this congestion is invisible in raw ClinicalTrials.gov downloads because hospital names appear under dozens of inconsistent strings (such as MDACC, M.D. Anderson (Site 0015), or IRB-prefixed clinic labels). Protocol Ledger executes 49,607 deterministic campus merges across 325,453 raw facility tuples while strictly preserving distinct geographic campuses (for example, keeping Mayo Clinic Rochester, Scottsdale/Phoenix, and Jacksonville separate).
| Canonical Medical Center Campus | City, State | Total Trials | Active Load | Recruiting Now | Completed | Stopped | Stop % |
|---|---|---|---|---|---|---|---|
| MD Anderson Cancer Center | Houston, TX | 1,694 | 1,087 | 576 | 256 | 313 | 18.48% |
| Washington University and Siteman Cancer Center | Saint Louis, MO | 1,592 | 902 | 437 | 417 | 243 | 15.26% |
| Memorial Sloan Kettering Cancer Center | New York, NY | 1,190 | 832 | 423 | 185 | 158 | 13.28% |
| Mayo Clinic Rochester | Rochester, MN | 1,349 | 780 | 380 | 355 | 188 | 13.94% |
| Ohio State University Comprehensive Cancer Center | Columbus, OH | 1,221 | 739 | 380 | 266 | 198 | 16.22% |
| Emory Winship Cancer Institute | Atlanta, GA | 1,258 | 719 | 371 | 315 | 195 | 15.50% |
| UCLA Health and Jonsson Comprehensive Cancer Center | Los Angeles, CA | 1,304 | 701 | 322 | 377 | 201 | 15.41% |
| Dana-Farber Cancer Institute | Boston, MA | 1,002 | 674 | 323 | 160 | 144 | 14.37% |
| Duke University Medical Center | Durham, NC | 1,172 | 664 | 342 | 311 | 182 | 15.53% |
| Northwestern Memorial and Lurie Cancer Center | Chicago, IL | 1,186 | 660 | 277 | 325 | 176 | 14.84% |
Gate 3, Gate 4 & Gate 5: M&A Lineage, Accrual Velocity, and Drugs@FDA Conversion
Consolidating Acquired Biotech Subsidiaries Across 37 Parent Trees
Evaluating a large biopharma acquirer or licensing partner on raw LeadSponsorName strings misses thousands of acquired clinical assets that remain registered under legacy biotech subsidiary names years after deal close. Protocol Ledger consolidates 3,327 subsidiary protocols across 156 distinct corporate names into 37 M&A parent trees (such as Seagen, Arena, and Biohaven under Pfizer; Celgene, Mirati, Karuna, Turning Point, and RayzeBio under Bristol Myers Squibb; Alexion, Acerta, CinCor, and Fusion under AstraZeneca; Allergan, Pharmacyclics, and ImmunoGen under AbbVie; and Loxo, DICE, Morphic, and POINT Biopharma under Eli Lilly). Auditing post-acquisition strategic stop spikes (WS2) shows how acquirers prune overlapping pipeline assets within 12 to 24 months of closing.
Benchmarking Enrollment Velocity and FDA NDA/BLA Conversion
Before underwriting a sponsor's projected primary completion quarter, calculate implied enrollment velocity (target_patients / disclosed_sites / planned_months) against the therapeutic-area medians in our ledger and verify historical regulatory execution across 2,830 sponsor-linked original NDA and BLA approvals from Drugs@FDA.
| Diligence Gate | Primary Registry Metric | Cohort Empirical Baseline | Practitioner Red Flag & Audit Action |
|---|---|---|---|
| 1. Site Congestion | Concurrent active Phase II/III protocols per hospital | 640 to 1,087 at top AMCs | 100% academic-hub concentration without dedicated community network sites |
| 2. Site Disclosure | Named hospital slots vs anonymized CRO placeholders | 83.66% named cohort-wide | <50% disclosed physical sites prevents independent geographic accrual checks |
| 3. Accrual Velocity | Target N vs indication median enrollment & days | 43 N / 1,269d (ONC); 113 N / 616d (END) | Projected completion <50% of indication median duration without biomarker breadth |
| 4. Status Hygiene | Verified recruiting updates vs stale UNKNOWN lag |
8,352 stale studies (15.22%) | Unupdated record >12 months or multiple Primary Completion Date pushouts |
| 5. M&A & FDA Lineage | Subsidiary stop history & linked Drugs@FDA approvals | 37 M&A trees / 2,830 NDAs/BLAs | Unconsolidated subsidiary safety stops (WS4) or zero prior pivotal completions |
Balancing Academic Prestige Against Dedicated Community Trial Networks
Sponsor execution profiles in Protocol Ledger show that biopharma teams achieving predictable completion medians in cardiometabolic, respiratory, immunology, and late-stage oncology programs pair flagship academic centers of excellence with dedicated multi-specialty community research networks. Community clinics typically carry far lower competing-protocol congestion per principal investigator, faster central IRB activation turnaround (often 3 to 5 weeks vs 4 to 7 months at academic medical centers), and broader geographic access to diverse patient populations across suburban and inland metro areas.
Methodology and Workbench Workflow
Practitioners can run side-by-side institutional and sponsor audits directly inside the Comparison Matrix (configured to compare up to four sponsors or medical centers simultaneously) and inspect regional hub patterns across Boston, New York, Houston, the San Francisco Bay Area, Los Angeles, San Diego, and the Midwest inside the 3D Site Capacity Map.